Category
HRSA Launches 340B Rebate Model Pilot Program: What Manufacturers Need to Know
The Health Resources and Services Administration (HRSA) has introduced a significant new development for the 340B Drug Pricing Program with the launch of its 340B Rebate Model Pilot Program. This initiative offers drug manufacturers a fresh, alternative pathway to comply with their 340B pricing obligations, aimed at addressing longstanding industry… Read More
President Trump Unveils Sweeping “Most Favored Nation” Drug Pricing Policy
On May 12, 2025, President Donald Trump announced a bold new policy proposal aimed at tackling one of the most persistent issues in American healthcare: the high cost of prescription drugs. The centerpiece of this announcement is the introduction of a “most favored nation” (MFN) model, a strategy that would… Read More